{"filings":[{"id":92483,"accession_number":"0001372514-26-000048","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q1 cash $13.9M, $5.0M equity raise post-quarter; KIO-301 enrollment nearly 50% in Phase 2","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 cash $13.9M; post-quarter raised $5.0M in equity from Perceptive Advisors; operational runway into late 2028.","Phase 2 ABACUS-2 enrollment for KIO-301 nearly 50% completed; trial sites expanding due to strong patient demand.","ABACUS-1 results published in Nature Medicine, validating KIO-301 photoswitch technology for vision restoration.","Phase 2 KLARITY study of KIO-104 progressing; safety review upcoming to enable dose escalation.","R&D expenses $2.1M with $1.2M Théa reimbursement; G&A $1.6M; collaboration receivables $1.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92482,"accession_number":"0001372514-26-000036","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals closes $5M private placement with Perceptive Advisors; warrants could add $19M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement raising $5.0M upfront; potential $19M from warrant exercise.","Sole investors: Perceptive Advisors and ADAR1 Capital Management; no placement agent engaged.","Each unit: 1 common share (or pre-funded warrant) + 4 Tranche A-1 + 1 Tranche A-2 warrants at $2.543.","All warrants exercisable at $1.94/share; A-1 term ≤9 months (30 days after strategic transaction), A-2 ≤4 years (30 days after Phase 3 enrollment).","Proceeds for general corporate purposes, including R&D and business development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92481,"accession_number":"0001372514-26-000028","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals CDO Eric Daniels to resign April 17; successor search initiated","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric J. Daniels resigns as Chief Development Officer effective April 17, 2026, to pursue other opportunities.","Resignation not due to any disagreement with company's operations, policies, or practices.","Company has initiated a search for Daniels' successor; CEO thanked Daniels for his contributions.","Kiora continues enrollment in KIO-301 (ABACUS-2) and KIO-104 (KLARITY) Phase 2 trials.","Safety reviews cleared for KIO-301 50µg and 100µg dose cohorts; KIO-104 enrollment ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103340,"accession_number":"0001372514-26-000025","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2026-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals reports FY2025 net loss of $10.8M; two Phase 2 trials underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $10.8M for 2025 vs net income of $3.6M in 2024 due to $16M upfront payment from Théa in prior year.","Cash, equivalents and short-term investments of $17.1M as of Dec 31, 2025; expects runway into late 2027.","KIO-301 Phase 2 ABACUS-2 trial for retinitis pigmentosa advancing; initial data readout expected Q3 2027.","KIO-104 Phase 2 KLARITY trial for macular edema dosing; non-cash impairment charge in Q4.","Executed option agreement with Senju for KIO-301 in Asia with potential value up to $110M plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119582,"accession_number":"0001372514-25-000079","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports Q3 net income of $27K; cash runway into late 2027; two Phase 2 trials enrolling","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and investments $19.4M; collaboration receivables $1.2M; tax receivables $1.5M.","R&D expense $2.7M (net of $1.7M Théa reimbursement) vs $2.1M in Q3 2024.","Q3 2025 net income $27K vs net loss of $3.4M in Q3 2024, driven by tax impacts and noncash gains.","Both Phase 2 trials — KLARITY (KIO-104 for retinal inflammation) and ABACUS-2 (KIO-301 for retinitis pigmentosa) — continue recruitment and dosing.","Received $1.2M in reimbursed R&D from Théa in Q3; billed an additional $1.5M in the quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136155,"accession_number":"0001372514-25-000068","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals furnishes updated investor presentation for H.C. Wainwright conference","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Filed 8-K on August 13, 2025 to disclose updated investor presentation (Exhibit 99.1).","Presentation prepared for H.C. Wainwright 5th Annual Ophthalmology Virtual Conference.","Company CFO Melissa Tosca signed the report as principal financial officer.","Data presented under Item 7.01 Regulation FD and not deemed filed for Exchange Act purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136154,"accession_number":"0001372514-25-000064","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q2 net loss $2.2M; initiated two Phase 2 retinal trials, Senju deal up to $110M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.2M in Q2 2025, flat YoY; cash and equivalents $20.7M, runway into late 2027.","KLARITY Phase 2 trial for KIO-104 in retinal inflammation initiated; patent exclusivity extended to 2043.","ABACUS-2 Phase 2 trial of KIO-301 for retinitis pigmentosa initiated with validated functional vision endpoint.","Option agreement with Senju for KIO-301 in Asia; potential deal value up to $110M plus royalties; $1.25M option fee received.","R&D expense $2.6M offset by $1.7M Théa reimbursement; G&A down to $1.4M from $1.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153223,"accession_number":"0001372514-25-000053","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-06-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Kiora shareholders elect directors, approve say-on-pay and auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Carmine Stengone and Brian M. Strem elected as Class I directors for three-year term.","Non-binding advisory vote on named executive officer compensation approved (1,144,829 for, 82,389 against).","Ratification of Haskell & White LLP as independent auditor for FY2025 passed (1,567,427 for, 78,598 against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153222,"accession_number":"0001372514-25-000050","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Kiora grants Senju exclusive option for KIO-301 in Asia; $1.25M upfront, up to $110M milestones plus royalties","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Immediate $1.25M option payment; if exercised, mid-single-digit million upfront and up to $110M in development, regulatory, and commercial milestones.","Tiered royalties from high single-digit to high teen percent on net sales; territory covers Japan, China, and other key Asian countries.","Option exercisable after topline data from ongoing ABACUS-2 Phase 2 trial; Senju to collaborate with Théa, Kiora's ex-Asia partner.","Combined deal value with Théa (2024) and Senju exceeds $400M plus royalties; cash runway extended into late 2027.","KIO-301 is a molecular photoswitch for retinitis pigmentosa and other inherited retinal diseases, currently in Phase 2."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153221,"accession_number":"0001372514-25-000045","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q1 net loss $2.2M; cash $24.1M into late 2027; initiates two Phase 2 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.2M vs net income $13.4M in Q1 2024 due to $16M upfront from Théa in prior year.","Cash & short-term investments $24.1M; runway extended into late 2027 beyond key data readouts.","Initiating Phase 2 KLARITY trial for KIO-104 (retinal inflammation) and ABACUS-2 for KIO-301 (retinitis pigmentosa); first patient enrollment expected Q2 2025.","Received $1.8M in reimbursed Q4 2024 R&D expenses from Laboratoires Théa; total $5.6M since collaboration began.","R&D expenses $2.5M (up from $1.7M) due to clinical trial activities; G&A $1.5M up from $1.3M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171996,"accession_number":"0001372514-25-000014","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.","Net income $3.6M in 2024 vs net loss $12.5M in 2023; Q4 2024 net loss $4.2M.","Received approval for KLARITY (Phase 2 KIO-104) and ABACUS-2 (Phase 2 KIO-301) studies.","Recognized $16M in collaboration revenue from Laboratoires Théa for KIO-301 in 2024.","Data readouts from both Phase 2 trials expected in 2026; first patient dosing in Q2 2025 for KLARITY."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171995,"accession_number":"0001372514-25-000003","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Kiora formalizes employment agreements with CFO and CDO; base salaries $337K and $443K","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Eric Daniels (CDO) receives $443,000 annual base salary, 40% bonus target, and $6,500/month relocation gross-up for 15 months.","Melissa Tosca (CFO) receives $337,000 annual base salary, 40% bonus target, and severance of 6 months' salary plus 0.5x max bonus.","Both agreements provide full equity acceleration upon a change of control and partial vesting on qualifying termination.","Daniels must reimburse 50% of relocation costs if he resigns or is fired for cause within 12 months.","Agreements executed January 10, 2025, effective January 1, 2025, for Daniels and formalizing Tosca's promotion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188988,"accession_number":"0001372514-24-000121","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Q3 net loss $3.4M; cash $29M; advancing two Phase 2 retinal trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $29.0M at Sept 30, plus $1.8M collaboration receivables; runway into 2027.","Net loss $3.4M vs $5.8M in Q3 2023; decrease due to -$1.1M non-cash change in contingent consideration.","R&D expenses net $1.3M after $0.9M Théa reimbursement; G&A flat at $1.4M.","IND approved for ABACUS-2 Phase 2 study of KIO-301 in retinitis pigmentosa; first patient dosing in 2025.","Phase 2 KLARITY trial of KIO-104 designed; submission for approval on track for Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":16020000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188987,"accession_number":"0001372514-24-000117","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiora receives IND approval for Phase 2 trial of KIO-301 in retinitis pigmentosa","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ABACUS-2 is a 36-patient, multi-center, double-masked, randomized, controlled Phase 2 trial.","Enrolling patients with ultra-low vision or no light perception regardless of gene mutation.","First patient dosing expected next year after validation of novel functional vision endpoints.","KIO-301 is a light-sensitive small molecule photoswitch targeting retinal ganglion cells.","Primary endpoints include safety, tolerability; key efficacy: functional vision and visual acuity tests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205467,"accession_number":"0001372514-24-000105","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports Q2 net loss $2.2M, cash $27.8M; advancing two Phase 2 retinal trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $20K (grant); net R&D expense $0.9M after $1.1M TOI reimbursement credits.","Cash, equivalents and short-term investments $27.8M; plus receivables/Tax credits $3.7M; runway into 2027.","Phase 2 ABACUS-2 trial of KIO-301 for retinitis pigmentosa design finalized; initiation expected 2H 2024.","Phase 2 CLARITY trial of KIO-104 for retinal inflammation planned to start 1H 2025, building on Phase 1b.","Melissa Tosca promoted to CFO; Lisa Walters-Hoffert appointed to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":2.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":16020000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205466,"accession_number":"0001372514-24-000099","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-07-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Kiora Pharma receives EU orphan designation for KIO-301 in inherited retinal dystrophies","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EMA grants Orphan Medicinal Product Designation for KIO-301 in non-syndromic rod-dominant retinal dystrophies including retinitis pigmentosa.","Provides at least 10 years of market exclusivity in Europe, reduced fees, centralized approval, and EMA scientific advice.","KIO-301 already has US Orphan Drug Designation; Phase 2 ABACUS-2 trial expected to initiate later in 2024.","KIO-301 is a small molecule photoswitch designed to restore light sensing in degenerated retinas, a non-gene therapy approach.","Co-development and commercialization partner Théa Open Innovation covers ex-Asia territories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205465,"accession_number":"0001372514-24-000068","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Kiora appoints Walters-Hoffert to board, promotes Tosca to CFO, regains Nasdaq compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa Walters-Hoffert appointed independent director and audit committee chair; Kenneth Gayron resigned.","Melissa Tosca promoted from EVP of Finance to CFO; salary raised to $337,000, bonus target to 40%.","CEO Brian Strem's salary increased to $569,000 (55% bonus); Chief Development Officer Daniels to $443,000 (40%).","New non-employee director compensation: initial 1,778 stock option grant, cash retainers up to $70,000 annually.","Regained compliance with Nasdaq minimum bid price rule (Nasdaq Listing Rule 5550(a)(2)) as of June 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222390,"accession_number":"0001372514-24-000057","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Kiora Pharmaceuticals announces 1-for-9 reverse stock split effective June 11, 2024 to meet Nasdaq bid price requirement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1-for-9 reverse stock split filed June 6, 2024; effective at open of market on June 11, 2024.","Outstanding shares will reduce from ~26.7M to ~2.97M; fully diluted from ~100.1M to ~11.1M.","Class D warrants for 3.43M shares expired on June 6, 2024; other warrants adjust proportionally.","No change to authorized shares, par value ($0.01), or ticker (KPRX); fractional shares paid in cash.","Reverse split is intended to maintain compliance with Nasdaq minimum bid price requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222389,"accession_number":"0001372514-24-000054","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora Pharma Q1 net income $13.5M on $16M TOI revenue; $31.3M cash; KIO-301 Phase 2 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Ended Q1 with $31.3M cash plus $1.8M R&D tax credits; runway over 2 years.","Revenue $16M from Théa Open Innovation upfront; net income $13.5M vs. $1.9M loss YoY.","Phase 2 ABACUS-2 trial for KIO-301 (retinitis pigmentosa) on track for Q4 2024 start.","Phase 2 trial for KIO-104 (retinal inflammation) expected to begin in 2025.","TOI deal includes up to $285M milestones and tiered royalties up to low-20% on sales."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":16000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222388,"accession_number":"0001372514-24-000039","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Kiora shareholders approve reverse stock split and increase authorized shares to 150M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split of common stock approved at a ratio between 1-for-2 and 1-for-10; board will set exact ratio and timing.","Authorized common shares increased to 150,000,000 total authorized shares of all classes to 160,000,000 (including 10M preferred).","Issuance of up to 49,374,590 common shares upon exercise of Tranche A and B Warrants from February 2024 private placement approved.","Proposal to adjust voting requirements for certain future amendments failed to pass.","David Hollander, MD, MBA and Erin Parsons elected as Class III directors for a three-year term ending at 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":241915,"accession_number":"0001372514-24-000027","cik":1372514,"company_name":"KIORA PHARMACEUTICALS INC","ticker":"KPRX","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.","Cash and equivalents $2.5M at year-end 2023; $16M upfront from TOI partnership and $13.8M private placement net proceeds in Feb 2024 raised cash >$30M.","Company expects existing cash to fund operations through 2026.","KIO-301 Phase 2 trial in retinitis pigmentosa expected to start Q4 2024; KIO-104 Phase 2 planning underway.","Partnership with Théa Open Innovation grants exclusive rights to KIO-301 outside Asia; potential milestones up to $285M plus tiered royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":12365112.6,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}